Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial

被引：3
|
作者：
Nakamura, Ryosuke [1 ]
Hirata, Takero [1 ]
Suzuki, Osamu [1 ]
Otani, Keisuke [1 ]
Kai, Naoki [1 ]
Hatano, Koji [2 ]
Fujita, Kazutoshi [2 ]
Uemura, Motohide [2 ]
Imamura, Ryoichi [2 ]
Tanaka, Kazunori [1 ]
Yoshioka, Yasuo [3 ]
Nonomura, Norio [2 ]
Ogawa, Kazuhiko [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Urol, Osaka, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Radiat Oncol, Tokyo, Japan
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 04期
关键词：
SBRT; CyberKnife; prostate cancer; INTENSITY-MODULATED RADIOTHERAPY; FRACTIONATION; BRACHYTHERAPY;
D O I：
10.21873/anticanres.14162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The present study aimed to evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for localized prostate cancer. Patients and Methods: We investigated 25 patients treated with SBRT of 35 Gy per five fractions from May 2014 to March 2015. Results: The median age of patients was 70 years, four (16%) patients were low risk and 21 (84%) were intermediate risk. Seven (28%) patients received neoadjuvant androgen-deprivation therapy. The median follow-up time was 53 months. Grade 2 acute and late genitourinary toxicities were observed in five (20%) and two (8%) patients and there were no Grade 2 gastrointestinal toxicities. There were no Grade 3 or higher acute or late toxicities at 2 years follow-up. The biochemical relapse-free survival rate at 2 years was 100%. Conclusion: SBRT of 35 Gy per five fractions is a promising treatment method in the short term for prostate cancer.
引用
收藏
页码：2053 / 2057
页数：5
相关论文
共 50 条
  • [31] Hypofractionated Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: A Multi-institutional Phase 2 Analysis
    Gill, B. S.
    Olsheski, M. E.
    DAmbrosio, D. J.
    Clump, D. A., II
    Wegner, R. E.
    Iyer, R.
    Burton, S. A.
    Holeva, K.
    Heron, D. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E197 - E198
  • [32] Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
    Shafak Aluwini
    Peter van Rooij
    Mischa Hoogeman
    Wim Kirkels
    Inger-Karine Kolkman-Deurloo
    Chris Bangma
    Radiation Oncology, 8
  • [33] A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer
    Okonogi, Noriyuki
    Tsuji, Hiroshi
    Kobayashi, Kana
    Nakajima, Mio
    Aoki, Shuri
    Utsumi, Takanobu
    Suzuki, Hiroyoshi
    Akakura, Koichiro
    Ichikawa, Tomohiko
    Ishikawa, Hitoshi
    ADVANCES IN RADIATION ONCOLOGY, 2025, 10 (03)
  • [34] Predictors of Acute Toxicity after Stereotactic Body Radiation Therapy for Low and Intermediate-risk Prostate Cancer: Secondary Analysis of a Phase I Trial
    Hong, D. S.
    Heinzerling, J. H.
    Lotan, Y.
    Cho, L. C.
    Brindle, J.
    Xie, X.
    Pistenmaa, D.
    Cooley, S.
    Boike, T.
    Timmerman, R. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S210 - S210
  • [35] Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study
    Katz, Alan Jay
    Kang, Josephine
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [36] A Prospective, Single-Arm, Phase II, Multi-Center Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
    Olson, A. C.
    Skiba, J. H.
    Gill, B. S.
    Wang, H.
    Davies, B.
    Holeva, K.
    D'Ambrosio, D.
    Wegner, R. E.
    Heron, D. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E288 - E289
  • [37] Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer
    Lee, Seok Ho
    Kim, Hun Jung
    Kim, Woo Chul
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (04) : 388 - 395
  • [38] CYBERKNIFE TREATMENT FOR LOW AND INTERMEDIATE RISK LOCALIZED PROSTATE CANCER
    Bolzicco, G.
    Scremin, E.
    Favretto, M. S.
    Tambone, C.
    Cavedon, C.
    Scalchi, P.
    Panizzoni, G. A.
    Baiocchi, C.
    Testolin, A.
    Mari, C.
    Messina, F.
    Tasca, A.
    Francescon, P.
    Guglielmi, R.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S317 - S318
  • [39] Low- and Intermediate-Risk Prostate Cancer. Stereotactic Body Radiation Therapy. Our experience.
    Garcia Aguilera, C.
    Mendez Villamon, A.
    Flamarique Andueza, S.
    Villa Gazulla, D.
    Escuin Troncho, C.
    Ponce Ortega, J. M.
    Puertas Valino, M. M.
    Tejedor Gutierrez, M.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S616 - S616
  • [40] Dose-Escalated Stereotactic Body Radiation Improves Outcomes in Patients with Low- and Intermediate-Risk Prostate Cancer
    Cox, B. W.
    Rana, Z.
    Lee, L.
    Potters, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E105 - E105
12345